Abstract
Reduction of nitro groups to amines is a fundamental transformation in the synthesis of several pharmaceutical drugs, including tyrosine kinase inhibitors. Industrial practice overwhelmingly favours the catalytic hydrogenation of nitroarenes using heterogeneous metals such as Ni, Pd, or Pt, owing to the method’s excellent atom economy, benign by‑product profile (water), and suitability for large‑scale operations. Raney nickel is often selected when palladium catalysts pose risks of dehalogenation or hydrogenolysis, providing a cost‑effective and robust alternative for bulk manufacturing.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Recommended Citation
Anonymous, "REDUCTION OF NITRO INTERMEDIATES OF ANTICANCER DRUGS USING RANEY NICKEL UNDER BASIC CONDITIONS", Technical Disclosure Commons, (March 11, 2026)
https://www.tdcommons.org/dpubs_series/9493